Trial Profile
A study evaluating selectivity of PAR-101 for C. difficile associated diarrhoea.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary) ; Vancomycin
- Indications Clostridium difficile infections; Diarrhoea
- Focus Therapeutic Use